Core Scientific, Inc. Tranche 2 Warrants closed at $16.67 on Sep 28, down 5.50%, 42.7% below its 52-week closing high. Volume of 4.4K shares was 0.77× its 20-day average (below normal).
Split-adjusted performance: -5.9% over one month, +10.3% over six months.
In the quarter ended Jun 30, 2026, revenue was $164.20M, up 108.8% from a year earlier, with a net margin of -658.4%.
Short interest was 825.4K shares at the Sep 15 settlement (116.4 days to cover).